Kamada, myTomorrows sales and marketing update

Kamada and myTomorrows launched an early access program (EAP) in Europe for Kamada’s highly purified alpha-1 antitrypsin ( AAT; A1AT; SERPINA1) to treat bone marrow transplant patients who develop s...